DAX-0,02 % EUR/USD+0,05 % Gold+0,10 % Öl (Brent)+0,43 %

CLINUVEL PHARMACEUTICALS LTD


ISIN: AU000000CUV3 | WKN: A0JEGY
11,320
19.09.18
Stuttgart
-1,74 %
-0,200 EUR

Beitrag schreiben

Begriffe und/oder Benutzer

 

Antwort auf Beitrag Nr.: 28.968.937 von paulmc am 24.04.07 13:00:35Wegen anstehender News auf Antrag von CUV selbst vom Handel in AUS ausgesetzt bis Freitag. Nachzulesen u.a. auf stocknessmonster.com

Gruß
Fritz
Antwort auf Beitrag Nr.: 28.969.565 von FritzFussbroich am 24.04.07 13:36:59Die Aktie wird ab Donnerstag wieder gehandelt - nachzulesen auf der Clinuvel HP.

Zitat:The trading halt is to last until the earlier of CUV releasing an announcement, or until
the commencement of trade on Thursday 26 April 2007, noting that Wednesday 25
April is a non business day for ASX purposes.

Das heißt - früh aufstehen oder munter bleiben.
Erste Kurse ab ca. 02:20 Uhr - unserer Zeit!
Antwort auf Beitrag Nr.: 28.970.353 von martinio am 24.04.07 14:15:45Korrekt! Hab nochmal nachgelesen, am Donnerstag gehts weiter. Hoffentlich mit guten News:yawn:

Fritz
...shit was ist das denn ... fast -10 % in Australien ..kann einer dieses Privat Placement erklären... irgendwie geben die etwa 24 Mio. neue Aktien zu 1,07 AUS $ aus, die nur Australier und Neuseeländer beziehen können...??? also Altaktionäre mal wieder beschissen oder wie??????
hier mal die Details:

Company Announcement
Thursday 26th April 2007
Melbourne, Australia

Clinuvel completes A$26 million Private Placement and announces a Share Purchase Plan for Australian investors Clinuvel Pharmaceuticals Limited (ASX:CUV, XETRA-DAX:UR9) is pleased to announce the completion of a successful private placement of 24,339,054 shares at $1.07, to Australian and European institutions resulting in a total of A$26 million.

Clinuvel also announces a Share Purchase Plan (SPP) to allow Australian shareholders to participate at the same price. The proceeds will be used to fund clinical trials of CUV1647 in the recently announced fifth indication in Photodynamic Therapy and to continue ongoing development of its technology. (See Use of
Proceeds)

The company’s strategic aim is to file for its first clinical registration in 2009 for its photo-protective drug
CUV1647. In line with this strategy, the company has recently received allowance from the UK’s Regulatory Agency (MHRA) to begin a pan-European Phase III trial of CUV1647 in Polymorphic Light Eruption (PLE) as well as allowance from the Swiss Regulatory Agency, Swissmedic, to begin a Phase III trial of CUV1647 in Erythropoietic Protoporphyria (EPP).

Clinuvel’s Executive Chairman, Dr Roger Aston said:
“With A$41.2 million raised in 2006 together with today’s over-subscribed placement, our cash reserves now
total $63.5 million and place Clinuvel in a favourable position to advance its plans to commercialise CUV1647 across five indications. Our cash balance, along with the safety and efficacy profile of CUV1647 to date, combine to diminish the company’s risk profile.”

Clinuvel’s CEO, Dr Philippe Wolgen said:
“Our recent clinical progress into Phase III trials in two indications has enhanced Clinuvel’s prospects for gaining market approval and our recent roadshow in Europe and Australia generated significant investor interest. Despite our substantial progress and a stronger than ever competitive outlook, we remain conscious
of the risks inherent in drug development.”

Use of Proceeds
• New indication – On 20 March 2007, Clinuvel announced that it had identified a fifth indication for its photo-protective drug CUV1647. This indication stems from a significant patient need for UVprotection following this type of cancer therapy. Phase II clinical trials in this indication are planned to begin in the second half of 2007. It is anticipated that CUV1647 will be shown to prevent the phototoxicity associated with Photodynamic Therapy (PDT) in cancer therapy.

• Accelerated clinical program for Erythropoietic Protoporphyria (EPP) – On 22 February 2007, Clinuvel announced positive preliminary results in a Phase II trial of CUV1647 in five EPP patients. This positive data led to a decision to proceed directly to a multicentre Phase III trial. On 11 April 2007 Clinuvel was granted allowance to begin a Phase III trial in Switzerland. The Phase III trial will be a double blind, placebo controlled and multicentre trial (sites across Europe and Australia). This
was the second Phase III approval granted to the Company in 2007.
The other Phase III trial, scheduled to begin in May 2007 will test whether CUV1647 prevents episodes or reduces the severity of Polymorphic Light Eruption (PMLE/PLE) symptoms in patients
with a documented history of PLE.

• New formulation – The bio-resorbable (fully dissolvable) implant that has been used in recent trials will continue to be used in 2007/2008. Clinuvel will increase its investment in manufacturing to ensure a suitable product formulation is available for registration purposes. We will continue to enhance our dosage forms. It is anticipated that technically advanced formulations will be available in the near future.

• Global recruitment – This year, Clinuvel is simultaneously conducting two Phase III trials and three Phase II trials across five indications globally. Clinuvel’s success requires an expanded regulatory and clinical team. Recruitment will start to build a clinical team in USA ahead of an FDA regulatory application (IND) to begin trials there.

The placement in Australia has been managed by JM Financial Group and sub-written by Australian and European institutions
Tag Zusammen,

wo ist der alte Thread hin, ?

kaum ist man ein paar Tage weg:laugh:
Antwort auf Beitrag Nr.: 29.023.356 von BKM am 26.04.07 23:16:49.... kein mensch weiß es -
********* es muss an Dir gelegen haben - warum warst du auch weg :mad:

:laugh:;):p
 Diskussion durchsuchen


Beitrag zu dieser Diskussion schreiben